167 related articles for article (PubMed ID: 30555330)
1. β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2.
Cheng H; Ge X; Zhuo S; Gao Y; Zhu B; Zhang J; Shang W; Xu D; Ge W; Shi L
Front Pharmacol; 2018; 9():1413. PubMed ID: 30555330
[TBL] [Abstract][Full Text] [Related]
2. β-Elemene Reverses Gefitinib Resistance in NSCLC Cells by Inhibiting lncRNA H19-Mediated Autophagy.
Zhang R; Zheng Y; Zhu Q; Gu X; Xiang B; Gu X; Xie T; Sui X
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794196
[TBL] [Abstract][Full Text] [Related]
3. Reversion of malignant phenotypes of human glioblastoma cells by β-elemene through β-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules.
Zhu T; Li X; Luo L; Wang X; Li Z; Xie P; Gao X; Song Z; Su J; Liang G
J Transl Med; 2015 Nov; 13():356. PubMed ID: 26563263
[TBL] [Abstract][Full Text] [Related]
4. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
5. NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.
Chiu CF; Chang YW; Kuo KT; Shen YS; Liu CY; Yu YH; Cheng CC; Lee KY; Chen FC; Hsu MK; Kuo TC; Ma JT; Su JL
Proc Natl Acad Sci U S A; 2016 May; 113(18):E2526-35. PubMed ID: 27091996
[TBL] [Abstract][Full Text] [Related]
6. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
8. mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines.
Terzuoli E; Costanza F; Ciccone V; Ziche M; Morbidelli L; Donnini S
Prostaglandins Other Lipid Mediat; 2019 Aug; 143():106344. PubMed ID: 31207300
[TBL] [Abstract][Full Text] [Related]
9. β-elemene suppresses tumor metabolism and stem cell-like properties of non-small cell lung cancer cells by regulating PI3K/AKT/mTOR signaling.
Cheng G; Li L; Li Q; Lian S; Chu H; Ding Y; Li C; Leng Y
Am J Cancer Res; 2022; 12(4):1535-1555. PubMed ID: 35530288
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
[TBL] [Abstract][Full Text] [Related]
12. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.
Lu Y; Liu Y; Oeck S; Glazer PM
Mol Cancer Res; 2018 Oct; 16(10):1458-1469. PubMed ID: 29934325
[TBL] [Abstract][Full Text] [Related]
14. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
[TBL] [Abstract][Full Text] [Related]
15. [Effect of Fuzheng Kang'ai Recipe Combined Gefitinib on Lung Cancer A549 Cells and Its Mecha- nism Research].
Yang XB; Chen X; Wu WY; Long SQ; Chen SM; Han SW
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Nov; 36(11):1340-1344. PubMed ID: 30641628
[TBL] [Abstract][Full Text] [Related]
16. Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells.
Miao L; Huang Z; Zengli Z; Li H; Chen Q; Yao C; Cai H; Xiao Y; Xia H; Wang Y
Oncotarget; 2016 Oct; 7(42):68339-68349. PubMed ID: 27577075
[TBL] [Abstract][Full Text] [Related]
17. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
19. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib.
Xu W; Wei Y; Wu S; Wang Y; Wang Z; Sun Y; Cheng SY; Wu J
Cell Biosci; 2015; 5():7. PubMed ID: 25973173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
